查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1588299

骨系统疾病市场规模、份额、趋势分析报告：按类型、治疗、症状、地区和细分市场预测，2025-2030

Skeletal Dysplasia Market Size, Share & Trends Analysis Report By Type (Achondroplasia, X-linked Hypophosphatemia, Hypophosphatasia), By Treatment, By Symptom, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 90 Pages | 商品交期: 2-10个工作天内

价格

骨系统疾病市场成长与趋势：

根据Grand View Research, Inc.最新报告，预计到2030年，全球骨系统疾病市场规模将达到38.5亿美元，2025年至2030年复合年增长率为2.0%。

该疾病的盛行率不断上升，尤其是在儿童中，以及孤儿药的日益采用可能有助于市场的扩张。

在各种疾病中，软骨发育不全是最常见的疾病。根据美国国家人类基因组研究所 2016 年发布的估计，每 15,000 至 40,000 人中就有 1 人患有软骨发育不全。目前，还没有专门针对软骨发育不全的核准治疗方法，但有五种治疗方法正在临床开发中。

这种疾病引起的遗传异常包括 FGFR3 基因的自然突变。 BioMarin 的 Vosoritide 以抑制 FGFR3途径为目标，是治疗软骨发育不全的First-in-Class药物。该药物正处于III期临床试验，预计2024年进入市场。 Clementia（易卜生集团）和 Regeneron 是针对多发性骨软骨瘤和进行性肌肉骨化症(FOP) 等疾病的其他市场参与者。这些管道药物在预测期内获得孤儿药核准预计将进一步推动骨病市场的成长。

药物根据疾病的遗传原因而有所不同，核准治疗方法XLH 和低磷酸酯酶症等疾病的药物包括 Ultragenics Pharmaceuticals 的 Crysvita 和 Alexion Pharmaceuticals 的 Strensiq。 Crysvita 于 2018 年获得 FDA核准，而 Strensiq 于 2015 年获得核准。 Strensiq 的销售额从 2015 年的 1,200 万美元增至 2018 年的 4.751 亿美元。这些孤儿药的使用量不断增加是市场成长的讯号。

骨系统疾病市场报告亮点

  • 低磷酸酯酶症 (HPP) 占据市场主导地位，2024 年占据最大销售份额，达到 48.5%。
  • 药物疗法引领市场，2024 年占最大销售份额，达 48.5%。
  • 骨骼畸形，包括副甲状腺疾病、荷尔蒙疗法以及脊椎和四肢截骨术，占据市场主导地位，2024年占最大销售份额，为20.9%。
  • 欧洲骨系统疾病市场主导全球市场，2024年占最大收益占有率为39.4%。

目录

第一章调查方法与范围

第 2 章执行摘要

第三章骨系统疾病市场的变数、趋势和范围

  • 市场体系展望
  • 市场动态
    • 市场驱动因素分析
    • 市场限制因素分析
  • 营商环境分析
    • 产业分析-波特五力分析
    • PESTLE分析

第四章骨系统疾病市场：依疾病类型进行的商业分析

  • 2024 年和 2030 年按疾病类型市场占有率
  • 故障类型细分仪表板
  • 2018-2030 年按残障类型分類的市场规模及预测与趋势分析
  • X连锁低血磷症（XLH）
  • 低磷酸酯酶症（HPP）
  • 软骨发育不全
  • 进行性肌肉骨化症(FOP)
  • 多发性骨软骨瘤 (MO)

第五章骨系统疾病市场：依治疗进行业务分析

  • 2024年及2030年治疗市场占有率
  • 治疗细分仪表板
  • 2018-2030年市场规模及预测与趋势分析、处理
  • 药品
  • 外科手术

第六章骨系统疾病市场：依症状进行业务分析

  • 2024 年及 2030 年症状市场占有率
  • 症状细分仪表板
  • 2018-2030 年市场规模、预测与趋势分析（按症状）
  • 骨骼变形
  • 牙齿畸形
  • 其他的

第七章骨系统疾病市场：区域估计与趋势分析

  • 2024 年及 2030 年区域市场占有率分析
  • 区域市场仪表板
  • 2018-2030年市场规模、预测趋势分析：
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 挪威
    • 丹麦
    • 瑞典
    • 俄罗斯
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 澳洲
    • 香港
    • 泰国
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中东/非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 科威特

第八章 竞争格局

  • 参与企业概况
  • 公司市场分析
  • 公司分类
  • 策略规划
  • 公司简介
    • BioMarin
    • Amgen Inc.
    • Merck KGaA
    • Regeneron
    • Alexion Pharmaceuticals, Inc.
    • Clementia（Ipsen Group）.
    • AstraZeneca plc.
    • Biomarin Pharmaceuticals Inc.
    • Cipla Ltd.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche AG.
    • Pfizer, Inc.
    • Teva Pharmaceutical Industries Ltd.
Product Code: GVR-3-68038-954-8

Skeletal Dysplasia Market Growth & Trends:

The global skeletal dysplasia market size is expected to reach USD 3.85 billion by 2030, registering a CAGR of 2.0% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increasing prevalence of this condition, especially in children, and growing adoption of orphan drugs are likely to contribute to the expansion of the market.

Among different disorders, achondroplasia is the most common condition. According to estimates published by the National Human Genome Research Institute in 2016, achondroplasia occurs in 1 in 15,000-40,000 live births. Although there are no current therapies approved specifically for achondroplasia, there are five therapies under clinical development.

Genetic defects attributable to the disorder include spontaneous mutations in the FGFR3 gene. Vosoritide by BioMarin targets inhibition of the FGFR3 pathway and presents a first-in-class drug for achondroplasia. The drug is in phase III clinical trial and is expected to enter the market in 2024. Clementia (Ipsen Group) and Regeneron are other market players targeting disorders such as multiple osteochondromas and fibrodysplasia ossificans progressiva (FOP). Approval of these pipeline therapies with orphan drug status during the forecast period will further support skeletal dysplasia market growth.

The medicines vary depending on the genetic cause of the disorder and only a handful of the disorders, such as XLH and hypophosphatasia, have approved curative therapies, including Ultragenyx Pharmaceuticals' Crysvita and Alexion Pharmaceuticals' Strensiq, respectively. Crysvita received FDA approval in 2018 whereas Strensiq received approval in 2015. The sales of Strensiq increased from USD 12.0 million in 2015 to USD 475.1 million in 2018. Higher uptake of these orphan drugs signal growth of the market.

Skeletal Dysplasia Market Report Highlights:

  • Hypophosphatasia (HPP) dominated the market and accounted for the largest revenue share of 48.5% in 2024 attributed to the increasing awareness and improved diagnostic capabilities, leading to more frequent diagnoses of this rare genetic disorder.
  • Medications led the market and accounted for the largest revenue share of 48.5% in 2024 attributed to the advancements in drug development and increased awareness of skeletal dysplasias.
  • Skeletal deformities, including parathyroid disorders, growth hormone therapies, and spinal and limb osteotomies, dominated the market and accounted for the largest revenue share of 20.9% in 2024.
  • Europe skeletal dysplasia market dominated the global market and accounted for the largest revenue share of 39.4% in 2024 attributed to heightened awareness and improved diagnostic capabilities.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Disorder Type
    • 1.2.2. Treatment
    • 1.2.3. Symptoms
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Skeletal Dysplasia Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Skeletal Dysplasia Market: Disorder Type Business Analysis

  • 4.1. Disorder Type Market Share, 2024 & 2030
  • 4.2. Disorder Type Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Disorder Type, 2018 to 2030 (USD Million)
  • 4.4. X-linked Hypophosphatemia (XLH)
    • 4.4.1. X-linked Hypophosphatemia (XLH) Market, 2018 - 2030 (USD Million)
  • 4.5. Hypophosphatasia (HPP)
    • 4.5.1. Hypophosphatasia (HPP) Market, 2018 - 2030 (USD Million)
  • 4.6. Achondroplasia
    • 4.6.1. Achondroplasia Market, 2018 - 2030 (USD Million)
  • 4.7. Fibrodysplasia Ossificans Progressive (FOP)
    • 4.7.1. Fibrodysplasia Ossificans Progressive (FOP) Market, 2018 - 2030 (USD Million)
  • 4.8. Multiple Osteochondromas (MO)
    • 4.8.1. Multiple Osteochondromas (MO) Market, 2018 - 2030 (USD Million)

Chapter 5. Skeletal Dysplasia Market: Treatment Business Analysis

  • 5.1. Treatment Market Share, 2024 & 2030
  • 5.2. Treatment Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2018 to 2030 (USD Million)
  • 5.4. Medication
    • 5.4.1. Medication Market, 2018 - 2030 (USD Million)
  • 5.5. Surgery
    • 5.5.1. Surgery Market, 2018 - 2030 (USD Million)

Chapter 6. Skeletal Dysplasia Market: Symptoms Business Analysis

  • 6.1. Symptoms Market Share, 2024 & 2030
  • 6.2. Symptoms Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Symptoms, 2018 to 2030 (USD Million)
  • 6.4. Skeletal Deformities
    • 6.4.1. Skeletal Deformities Market, 2018 - 2030 (USD Million)
  • 6.5. Dental Deformities
    • 6.5.1. Dental Deformities Market, 2018 - 2030 (USD Million)
  • 6.6. Others
    • 6.6.1. Others Market, 2018 - 2030 (USD Million)

Chapter 7. Skeletal Dysplasia Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. North America Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Regulatory Framework
      • 7.4.2.3. Competitive Insights
      • 7.4.2.4. U.S. Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Regulatory Framework
      • 7.4.3.3. Competitive Insights
      • 7.4.3.4. Canada Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Regulatory Framework
      • 7.4.4.3. Competitive Insights
      • 7.4.4.4. Mexico Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.5. Europe
    • 7.5.1. Europe Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Regulatory Framework
      • 7.5.2.3. Competitive Insights
      • 7.5.2.4. UK Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Regulatory Framework
      • 7.5.3.3. Competitive Insights
      • 7.5.3.4. Germany Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Regulatory Framework
      • 7.5.4.3. Competitive Insights
      • 7.5.4.4. France Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Regulatory Framework
      • 7.5.5.3. Competitive Insights
      • 7.5.5.4. Italy Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Regulatory Framework
      • 7.5.6.3. Competitive Insights
      • 7.5.6.4. Spain Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.7. Norway
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Regulatory Framework
      • 7.5.7.3. Competitive Insights
      • 7.5.7.4. Norway Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.8. Denmark
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Regulatory Framework
      • 7.5.8.3. Competitive Insights
      • 7.5.8.4. Denmark Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.5.9. Sweden
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Regulatory Framework
      • 7.5.9.3. Competitive Insights
      • 7.5.9.4. Sweden Skeletal Dysplasia Market Estimates and Forecastsasts, 2018 - 2030 (USD Million)
    • 7.5.10. Russia
      • 7.5.10.1. Key Country Dynamics
      • 7.5.10.2. Regulatory Framework
      • 7.5.10.3. Competitive Insights
      • 7.5.10.4. Russia Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Regulatory Framework
      • 7.6.2.3. Competitive Insights
      • 7.6.2.4. Japan Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Regulatory Framework
      • 7.6.3.3. Competitive Insights
      • 7.6.3.4. China Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Regulatory Framework
      • 7.6.4.3. Competitive Insights
      • 7.6.4.4. India Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.5. South Korea
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Regulatory Framework
      • 7.6.5.3. Competitive Insights
      • 7.6.5.4. South Korea Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.6. Australia
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Regulatory Framework
      • 7.6.6.3. Competitive Insights
      • 7.6.6.4. Australia Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.7. Hong Kong
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Regulatory Framework
      • 7.6.7.3. Competitive Insights
      • 7.6.7.4. Hong Kong Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.6.8. Thailand
      • 7.6.8.1. Key Country Dynamics
      • 7.6.8.2. Regulatory Framework
      • 7.6.8.3. Competitive Insights
      • 7.6.8.4. Thailand Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.7. Latin America
    • 7.7.1. Latin America Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Regulatory Framework
      • 7.7.2.3. Competitive Insights
      • 7.7.2.4. Brazil Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Regulatory Framework
      • 7.7.3.3. Competitive Insights
      • 7.7.3.4. Argentina Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 7.8. MEA
    • 7.8.1. MEA Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Regulatory Framework
      • 7.8.2.3. Competitive Insights
      • 7.8.2.4. South Africa Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Regulatory Framework
      • 7.8.3.3. Competitive Insights
      • 7.8.3.4. Saudi Arabia Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Regulatory Framework
      • 7.8.4.3. Competitive Insights
      • 7.8.4.4. UAE Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Regulatory Framework
      • 7.8.5.3. Competitive Insights
      • 7.8.5.4. Kuwait Skeletal Dysplasia Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. BioMarin
      • 8.5.1.1. Company Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. Amgen Inc.
      • 8.5.2.1. Company Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Merck KGaA
      • 8.5.3.1. Company Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Regeneron
      • 8.5.4.1. Company Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Alexion Pharmaceuticals, Inc.
      • 8.5.5.1. Company Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Clementia (Ipsen Group).
      • 8.5.6.1. Company Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. AstraZeneca plc.
      • 8.5.7.1. Company Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Biomarin Pharmaceuticals Inc.
      • 8.5.8.1. Company Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Cipla Ltd.
      • 8.5.9.1. Company Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Eli Lilly and Company
      • 8.5.10.1. Company Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives
    • 8.5.11. F. Hoffmann-La Roche AG.
      • 8.5.11.1. Company Overview
      • 8.5.11.2. Financial Performance
      • 8.5.11.3. Product Benchmarking
      • 8.5.11.4. Strategic Initiatives
    • 8.5.12. Pfizer, Inc.
      • 8.5.12.1. Company Overview
      • 8.5.12.2. Financial Performance
      • 8.5.12.3. Product Benchmarking
      • 8.5.12.4. Strategic Initiatives
    • 8.5.13. Teva Pharmaceutical Industries Ltd.
      • 8.5.13.1. Company Overview
      • 8.5.13.2. Financial Performance
      • 8.5.13.3. Product Benchmarking
      • 8.5.13.4. Strategic Initiatives

List of Tables

  • Table 1 List of Secondary Sources
  • Table 2 List of Abbreviations
  • Table 3 Global Skeletal Dysplasia Market, by Region, 2018 - 2030 (USD Million)
  • Table 4 Global Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
  • Table 5 Global Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 6 Global Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
  • Table 7 North America Skeletal Dysplasia Market, by country, 2018 - 2030 (USD Million)
  • Table 8 North America Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
  • Table 9 North America Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 10 North America Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
  • Table 11 U.S Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
  • Table 12 U.S Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 13 U.S Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
  • Table 14 Canada Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
  • Table 15 Canada Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 16 Canada Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
  • Table 17 Mexico Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
  • Table 18 Mexico Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 19 Mexico Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
  • Table 20 Europe Skeletal Dysplasia Market, by country, 2018 - 2030 (USD Million)
  • Table 21 Europe Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
  • Table 22 Europe Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 23 Europe Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
  • Table 24 UK Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
  • Table 25 UK Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 26 UK Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
  • Table 27 Germany Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
  • Table 28 Germany Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 29 Germany Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
  • Table 30 France Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
  • Table 31 France Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 32 France Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
  • Table 33 Italy Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
  • Table 34 Italy Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 35 Italy Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
  • Table 36 Spain Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
  • Table 37 Spain Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 38 Spain Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
  • Table 39 Norway Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
  • Table 40 Norway Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 41 Norway Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
  • Table 42 Denmark Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
  • Table 43 Denmark Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 44 Denmark Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
  • Table 45 Sweden Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
  • Table 46 Sweden Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 47 Sweden Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
  • Table 48 Asia Pacific Skeletal Dysplasia Market, by country, 2018 - 2030 (USD Million)
  • Table 49 Asia Pacific Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
  • Table 50 Asia Pacific Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 51 Asia Pacific Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
  • Table 52 Japan Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
  • Table 53 Japan Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 54 Japan Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
  • Table 55 China Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
  • Table 56 China Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 57 China Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
  • Table 58 India Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
  • Table 59 India Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 60 India Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
  • Table 61 Australia Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
  • Table 62 Australia Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 63 Australia Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
  • Table 64 South Korea Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
  • Table 65 South Korea Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 66 South Korea Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
  • Table 67 Thailand Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
  • Table 68 Thailand Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 69 Thailand Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
  • Table 70 Latin America Skeletal Dysplasia Market, by country, 2018 - 2030 (USD Million)
  • Table 71 Latin America Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
  • Table 72 Latin America Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 73 Latin America Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
  • Table 74 Brazil Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
  • Table 75 Brazil Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 76 Brazil Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
  • Table 77 Argentina Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
  • Table 78 Argentina Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 79 Argentina Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
  • Table 80 Middle East & Africa Skeletal Dysplasia Market, by country, 2018 - 2030 (USD Million)
  • Table 81 Middle East & Africa Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
  • Table 82 Middle East & Africa Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 83 Middle East & Africa Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
  • Table 84 South Africa Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
  • Table 85 South Africa Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 86 South Africa Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
  • Table 87 Saudi Arabia Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
  • Table 88 Saudi Arabia Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 89 Saudi Arabia Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
  • Table 90 UAE Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
  • Table 91 UAE Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 92 UAE Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)
  • Table 93 Kuwait Skeletal Dysplasia Market, by Disorder Type, 2018 - 2030 (USD Million)
  • Table 94 Kuwait Skeletal Dysplasia Market, by Treatment, 2018 - 2030 (USD Million)
  • Table 95 Kuwait Skeletal Dysplasia Market, by Symptoms, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Skeletal Dysplasia market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Segment outlook
  • Fig. 10 Segment outlook
  • Fig. 11 Competitive landscape
  • Fig. 12 Skeletal dysplasia market dynamics
  • Fig. 13 Skeletal dysplasia market: Porter's five forces analysis
  • Fig. 14 Skeletal dysplasia market: PESTLE analysis
  • Fig. 15 Skeletal dysplasia market: Disorder Type segment dashboard
  • Fig. 16 Skeletal dysplasia market: Disorder Type market share analysis, 2024 & 2030
  • Fig. 17 X-linked hypophosphatemia (XLH) market, 2018 - 2030 (USD Million)
  • Fig. 18 Hypophosphatasia (HPP) market, 2018 - 2030 (USD Million)
  • Fig. 19 Achondroplasia market, 2018 - 2030 (USD Million)
  • Fig. 20 Fibrodysplasia ossificans progressive (FOP) market, 2018 - 2030 (USD Million)
  • Fig. 21 Multiple osteochondromas (MO) market, 2018 - 2030 (USD Million)
  • Fig. 22 Skeletal dysplasia market: Treatment segment dashboard
  • Fig. 23 Skeletal dysplasia market: Treatment market share analysis, 2024 & 2030
  • Fig. 24 Medication market, 2018 - 2030 (USD Million)
  • Fig. 25 Surgery market, 2018 - 2030 (USD Million)
  • Fig. 26 Skeletal dysplasia market: Symptoms segment dashboard
  • Fig. 27 Skeletal dysplasia market: Symptoms market share analysis, 2024 & 2030
  • Fig. 28 Skeletal deformities market, 2018 - 2030 (USD Million)
  • Fig. 29 Dental deformities laboratories market, 2018 - 2030 (USD Million)
  • Fig. 30 Others market, 2018 - 2030 (USD Million)
  • Fig. 31 Skeletal dysplasia market revenue, by region
  • Fig. 32 Regional marketplace: Key takeaways
  • Fig. 33 Regional marketplace: Key takeaways
  • Fig. 34 North America skeletal dysplasia market, 2018 - 2030 (USD Million)
  • Fig. 35 U.S. country dynamics
  • Fig. 36 U.S. skeletal dysplasia market, 2018 - 2030 (USD Million)
  • Fig. 37 Canada country dynamics
  • Fig. 38 Canada skeletal dysplasia market, 2018 - 2030 (USD Million)
  • Fig. 39 Mexico country dynamics
  • Fig. 40 Mexico skeletal dysplasia market, 2018 - 2030 (USD Million)
  • Fig. 41 Europe skeletal dysplasia market, 2018 - 2030 (USD Million)
  • Fig. 42 UK country dynamics
  • Fig. 43 UK skeletal dysplasia market, 2018 - 2030 (USD Million)
  • Fig. 44 Germany country dynamics
  • Fig. 45 Germany skeletal dysplasia market, 2018 - 2030 (USD Million)
  • Fig. 46 France country dynamics
  • Fig. 47 France skeletal dysplasia market, 2018 - 2030 (USD Million)
  • Fig. 48 Italy country dynamics
  • Fig. 49 Italy skeletal dysplasia market, 2018 - 2030 (USD Million)
  • Fig. 50 Spain country dynamics
  • Fig. 51 Spain skeletal dysplasia market, 2018 - 2030 (USD Million)
  • Fig. 52 Norway country dynamics
  • Fig. 53 Norway skeletal dysplasia market, 2018 - 2030 (USD Million)
  • Fig. 54 Sweden country dynamics
  • Fig. 55 Sweden skeletal dysplasia market, 2018 - 2030 (USD Million)
  • Fig. 56 Denmark country dynamics
  • Fig. 57 Denmark skeletal dysplasia market, 2018 - 2030 (USD Million)
  • Fig. 58 Asia Pacific skeletal dysplasia market, 2018 - 2030 (USD Million)
  • Fig. 59 Japan country dynamics
  • Fig. 60 Japan skeletal dysplasia market, 2018 - 2030 (USD Million)
  • Fig. 61 China country dynamics
  • Fig. 62 China skeletal dysplasia market, 2018 - 2030 (USD Million)
  • Fig. 63 India country dynamics
  • Fig. 64 India skeletal dysplasia market, 2018 - 2030 (USD Million)
  • Fig. 65 Australia country dynamics
  • Fig. 66 Australia skeletal dysplasia market, 2018 - 2030 (USD Million)
  • Fig. 67 South Korea country dynamics
  • Fig. 68 South Korea skeletal dysplasia market, 2018 - 2030 (USD Million)
  • Fig. 69 Thailand country dynamics
  • Fig. 70 Thailand skeletal dysplasia market, 2018 - 2030 (USD Million)
  • Fig. 71 Latin skeletal dysplasia Dysplasia market, 2018 - 2030 (USD Million)
  • Fig. 72 Brazil country dynamics
  • Fig. 73 Brazil skeletal dysplasia market, 2018 - 2030 (USD Million)
  • Fig. 74 Argentina country dynamics
  • Fig. 75 Argentina skeletal dysplasia market, 2018 - 2030 (USD Million)
  • Fig. 76 MEA Skeletal Dysplasia market, 2018 - 2030 (USD Million)
  • Fig. 77 South Africa country dynamics
  • Fig. 78 South Africa skeletal dysplasia market, 2018 - 2030 (USD Million)
  • Fig. 79 Saudi Arabia country dynamics
  • Fig. 80 Saudi Arabia skeletal dysplasia market, 2018 - 2030 (USD Million)
  • Fig. 81 UAE country dynamics
  • Fig. 82 UAE skeletal dysplasia market, 2018 - 2030 (USD Million)
  • Fig. 83 Kuwait Key country dynamics
  • Fig. 84 Kuwait skeletal dysplasia market, 2018 - 2030 (USD Million)
  • Fig. 85 Company categorization
  • Fig. 86 Company market position analysis
  • Fig. 87 Strategic framework